New York State Common Retirement Fund bought a new position in shares of Calithera Biosciences, Inc. (NASDAQ:CALA) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 32,700 shares of the biotechnology company’s stock, valued at approximately $486,000. New York State Common Retirement Fund owned approximately 0.09% of Calithera Biosciences as of its most recent SEC filing.
Other hedge funds have also recently added to or reduced their stakes in the company. FMR LLC boosted its holdings in Calithera Biosciences by 278.2% during the first quarter. FMR LLC now owns 1,462,190 shares of the biotechnology company’s stock valued at $16,888,000 after purchasing an additional 1,075,592 shares in the last quarter. Goldman Sachs Group Inc. raised its stake in shares of Calithera Biosciences by 729.7% in the first quarter. Goldman Sachs Group Inc. now owns 133,981 shares of the biotechnology company’s stock valued at $1,547,000 after acquiring an additional 117,832 shares during the last quarter. Morgan Stanley raised its stake in shares of Calithera Biosciences by 1,053.6% in the first quarter. Morgan Stanley now owns 98,161 shares of the biotechnology company’s stock valued at $1,133,000 after acquiring an additional 89,652 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Calithera Biosciences by 249.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 71,600 shares of the biotechnology company’s stock valued at $1,064,000 after acquiring an additional 51,100 shares during the last quarter. Finally, Paloma Partners Management Co bought a new position in shares of Calithera Biosciences in the first quarter valued at approximately $160,000. 71.03% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://stocknewstimes.com/2017/11/23/new-york-state-common-retirement-fund-purchases-shares-of-32700-calithera-biosciences-inc-cala.html.
In related news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the stock in a transaction that occurred on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 16.30% of the company’s stock.
Calithera Biosciences, Inc. (NASDAQ CALA) opened at $10.75 on Thursday. Calithera Biosciences, Inc. has a 52-week low of $2.90 and a 52-week high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Thursday, November 2nd. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. The business had revenue of $7.20 million for the quarter, compared to analyst estimates of $6.02 million. equities research analysts predict that Calithera Biosciences, Inc. will post -0.77 earnings per share for the current year.
Several brokerages have recently issued reports on CALA. William Blair began coverage on shares of Calithera Biosciences in a report on Thursday, October 5th. They issued an “outperform” rating for the company. Zacks Investment Research raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Monday, November 6th. Finally, BidaskClub lowered shares of Calithera Biosciences from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Calithera Biosciences currently has a consensus rating of “Buy” and a consensus target price of $15.17.
Calithera Biosciences Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.